Molecular Matrix

Molecular Matrix, Inc. is a biotechnology and biomedical engineering company founded in 2011, headquartered in Rancho Cordova, California, specializing in next-generation osteobiologic technologies and bone regeneration solutions. The company's flagship product, Osteo-P® BGS (bone graft substitute), is a hyper-crosslinked carbohydrate polymer that received FDA 510(k) clearance in 2017. Osteo-P® BGS is designed to address critical challenges in orthopedic reconstruction, spine surgery, and trauma care by providing an osteoconductive synthetic scaffold that mimics the physiologic microenvironment for bone growth and repair. The product features superior porosity (75–95%) with optimal pore size (200–500 µm), is radiolucent for real-time radiographic visualization, and features a controlled degradation profile that matches new bone formation. As a synthetic, non-immunogenic, disease-transmission-free scaffold, Osteo-P® BGS offers surgeons a ready-to-use, reliable alternative to allograft and autograft materials. Under the leadership of CEO Charles Lee, Ph.D., Molecular Matrix develops therapeutics inspired by embryonic development and physiologic principles to accelerate healing, promote faster recovery, and enhance patient safety in musculoskeletal repair. The company serves orthopedic, spine, and trauma markets, positioning its osteobiologic platform for fracture repair, reconstruction, and degenerative tissue applications.